Extended Data Fig. 1: Cohort characteristics. | Nature Medicine

Extended Data Fig. 1: Cohort characteristics.

From: Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial

Extended Data Fig. 1

The enrolled criteria and conducted analyses of main patient cohorts included in this study (a–d). scRNA-seq, single-cell RNA sequencing; MIBI-TOF, multiplexed ion beam imaging by time of flight; apMC, antigen-presenting mast cell; R, responsive; NR, not responsive; ICI, immune-checkpoint inhibitor; Pembro, pembrolizumab; Camre, camrelizumab; Chemo, chemotherapy; ORR, objective response rate; pCR, pathologic complete response; PFS, progression-free survival; OS, overall survival; DFS, disease-free survival; mIHC, multiplex immunohistochemistry; n/a, not available. # One patient had available ORR evaluation but missed PFS data.

Back to article page